Intention to Float on AIM

Evgen Pharma plc, a clinical stage drug development company focused on the treatment of cancer and neurological conditions, today announces its intention to join the AIM market of the London Stock Exchange by way of a Placing to raise approximately £5 million.

Highlights

·     Evgen Pharma is a clinical stage drug development company focused on cancer and neurological conditions.  Its core technology Sulforadex® is a patent-protected method of stabilising a synthetic version of sulforaphane, which is a naturally occurring,  known anti-cancer agent derived from broccoli and other brassica vegetables

·     More than 1,200 peer-reviewed scientific articles support the therapeutic potential of sulforaphane though its commercial development has been prevented by its instability

·     Evgen Pharma is developing a pipeline of compounds based on its Sulforadex® technology and is pursuing clinical programmes in breast cancer and stroke along with earlier stage work in multiple sclerosis.  The Company's objective is to establish a dominant position in the development of pharmaceuticals based on sulforaphane and related analogues

·     Evgen Pharma has a highly experienced management, scientific and advisory team led by Executive Chairman Barry Clare, the former Boots Company plc director, and CEO Dr Stephen Franklin

·     Evgen Pharma is seeking to raise a minimum of £5 million in an IPO on AIM with trading in its shares expected to commence in October 2015.  The use of proceeds will include funding for a Phase IIa study in metastatic  breast cancer, a Phase II study in subarachnoid haemorrhage (a type of stroke) and preclinical studies in multiple sclerosis 

·     Northland Capital Partners is the Company's Nominated Adviser and Broker

Evgen Pharma's CEO, Dr Stephen Franklin, commented: "The anti-cancer and anti-inflammatory properties of sulforaphane are well documented and are supported by a wealth of published peer-reviewed scientific papers.  Our exciting Sulforadex® technology stabilises the molecule and unlocks its commercial potential, representing a major breakthrough as a potential therapy in cancer, neurology and other disease areas.  We intend to advance our programmes in breast cancer, stroke and multiple sclerosis through this IPO on the AIM market of the London Stock Exchange."

 

Suggested Articles

Reata’s bardoxolone improved kidney function in a phase 3 trial of patients with a rare form of chronic kidney disease.

The suit alleges the FDA imposed the hold “without notice or explanation” and has since “rebuffed” Regenxbio’s repeated requests for an explanation.

Bolt Biotherapeutics presented positive results from animal trials of its lead drug, a tumor-targeting antibody connected to an immune stimulator.